GeneReach Biotechnology (4171) - Total Assets
Based on the latest financial reports, GeneReach Biotechnology (4171) holds total assets worth NT$881.05 Million TWD (≈ $27.76 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GeneReach Biotechnology (4171) shareholders funds for net asset value and shareholders' equity analysis.
GeneReach Biotechnology - Total Assets Trend (2017–2025)
This chart illustrates how GeneReach Biotechnology's total assets have evolved over time, based on quarterly financial data.
GeneReach Biotechnology - Asset Composition Analysis
Current Asset Composition (December 2025)
GeneReach Biotechnology's total assets of NT$881.05 Million consist of 55.0% current assets and 45.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 17.6% |
| Accounts Receivable | NT$39.36 Million | 4.5% |
| Inventory | NT$32.56 Million | 3.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how GeneReach Biotechnology's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4171 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneReach Biotechnology's current assets represent 55.0% of total assets in 2025, an increase from 46.9% in 2017.
- Cash Position: Cash and equivalents constituted 17.6% of total assets in 2025, down from 19.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
GeneReach Biotechnology Competitors by Total Assets
Key competitors of GeneReach Biotechnology based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
GeneReach Biotechnology - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.41 | 2.48 | 3.72 |
| Quick Ratio | 2.25 | 2.33 | 2.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$283.03 Million | NT$355.14 Million | NT$650.00 Million |
GeneReach Biotechnology - Advanced Valuation Insights
This section examines the relationship between GeneReach Biotechnology's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -17.4% |
| Total Assets | NT$881.05 Million |
| Market Capitalization | $34.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values GeneReach Biotechnology's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GeneReach Biotechnology's assets decreased by 17.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GeneReach Biotechnology (2017–2025)
The table below shows the annual total assets of GeneReach Biotechnology from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$881.05 Million ≈ $27.76 Million |
-17.39% |
| 2024-12-31 | NT$1.07 Billion ≈ $33.60 Million |
-9.32% |
| 2023-12-31 | NT$1.18 Billion ≈ $37.05 Million |
-27.48% |
| 2022-12-31 | NT$1.62 Billion ≈ $51.10 Million |
-3.71% |
| 2021-12-31 | NT$1.68 Billion ≈ $53.07 Million |
+35.78% |
| 2020-12-31 | NT$1.24 Billion ≈ $39.08 Million |
+63.04% |
| 2019-12-31 | NT$760.87 Million ≈ $23.97 Million |
+9.66% |
| 2018-12-31 | NT$693.83 Million ≈ $21.86 Million |
+15.09% |
| 2017-12-31 | NT$602.84 Million ≈ $18.99 Million |
-- |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more